| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -43,165 | -8,945 | -57,119 | -80,348 |
| Depreciation of property and equipment | 5,918 | 5,182 | 4,306 | 8,951 |
| Amortization and impairment of intangible assets | NaN | 3,732 | NaN | NaN |
| Amortization of intangible assets | -1,871 | NaN | 940 | 1,851 |
| Amortization of operating lease right-of-use assets | 1,817 | 1,797 | 1,990 | 2,863 |
| Stock-based compensation | 12,013 | 12,904 | 13,895 | 28,993 |
| Fair value (gain)/loss on contingent consideration | NaN | NaN | -613 | NaN |
| Fair value (gain) loss on contingent consideration and investments | NaN | -4,529 | NaN | NaN |
| Other | -2,377 | 4,319 | -1,655 | 667 |
| Research fees and grants receivable | -13,103 | 39,666 | 3,433 | 12,524 |
| Income taxes payable | -4,970 | -10,051 | -12,204 | -7,588 |
| Accounts payable and accrued liabilities | -9,406 | 5,743 | 5,070 | -7,356 |
| Deferred revenue | -8,033 | -4,511 | -7,045 | 9,361 |
| Deferred grant income | 2,356 | 804 | 1,153 | 1,681 |
| Fair value gain on contingent consideration | NaN | NaN | NaN | -737 |
| Other assets | 1,741 | -3,070 | -628 | -13,450 |
| Net cash used in operating activities | -33,523 | -34,743 | -52,594 | -43,958 |
| Purchases of property and equipment | 3,831 | 9,843 | 8,928 | 24,001 |
| Purchase of marketable securities | 166,308 | 111,340 | 33,162 | 291,542 |
| Distribution from equity accounted investees | NaN | 30,113 | NaN | NaN |
| Investment in and loans to equity accounted investees | NaN | 251 | 2,451 | 4,435 |
| Proceeds from marketable securities | 143,802 | 119,536 | 83,099 | 303,437 |
| Proceeds from repayment of loan from joint venture partner | NaN | -33,268 | NaN | NaN |
| Receipt of grant funding | 1,361 | 13,977 | 918 | 6,448 |
| Long-term investments and other assets | 105 | 322 | 2,988 | 13,783 |
| Net cash provided by (used in) investing activities | -25,081 | 75,138 | 36,488 | -23,876 |
| Payment of liability for in-licensing agreement and other | NaN | 6,409 | 9,240 | NaN |
| Proceeds from long-term liabilities and other | -12,015 | NaN | 7,554 | 11,653 |
| Payment of contingent consideration and other | NaN | NaN | NaN | 9,058 |
| Proceeds from long-term liabilities and other | NaN | 29,731 | NaN | NaN |
| Net cash provided by financing activities | 7,192 | 4,115 | 7,372 | 2,595 |
| Effect of exchange rate changes on cash and cash equivalents | -38 | 290 | -544 | 1,351 |
| Increase (decrease) in cash and cash equivalents | -51,450 | 44,800 | -9,278 | -63,888 |
| Cash and cash equivalents and restricted cash, beginning of period | 155,249 | 110,449 | 183,615 | NaN |
| Cash and cash equivalents and restricted cash, end of period | 103,799 | 155,249 | 110,449 | NaN |
AbCellera Biologics Inc. (ABCL)
AbCellera Biologics Inc. (ABCL)